Evaluation of the Effect of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease
Authors
Adi Lahat (ORCID: https://orcid.org/0000-0003-1513-7280)
Evaluation of the Effect of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease
Adi Lahat, Jasmina Kalabic, Ronilda D’Cunha, Yinuo Pang et al.
Citations
1 citations
Journal
Clinical Pharmacokinetics
Topics
Pharmacogenetics and Drug Metabolism
Field-Weighted Citation Impact (FWCI)
0.47
article
Evaluation of the Effect of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease
Adi Lahat, Jasmina Kalabic, Ronilda D’Cunha, Yinuo Pang, Toni Anschutz, Tofial Azam
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
Clinical PharmacokineticsVol. 64(1)
Institutions
Ben-Gurion University of the Negev (IL), Tel Aviv University (IL), Sheba Medical Center (IL), AbbVie (United States) (US), AbbVie (Germany) (DE)